The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was over. It said the Danish pharmaceutical had sufficient supply of its semaglutide therapies to meet current and future,

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving the broader market in the dust.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom in the fourth quarter of last year,

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug.

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes drugs by 38% to $139B. REad more here.